Sweden has become the first country in the world where medical cannabis oil is being produced by a government owned company.
Doctors at a pain clinic in Stockholm have been prescribing cannabis oil to patients with a number of different indications, such as chronic neuropathic pain, arthritis, and rheumatism. This has led to medical cannabis oils finally being produced in Sweden.
It is a government owned company with a laboratory for pharmaceutical manufacturing that is now producing cannabis oil for medical use in Sweden.
The preparations are what is called “extempore” or “magistral” preparations in the pharmaceutical industry, and contain both CBD and THC i liquid form for drip dosing. More than 500 Swedish patients have received prescriptions for the cannabis oils from their doctors.
Medical cannabis has been available as a registered pharmaceutical in Sweden since 2011 when Sativex, a mouth spray with cannabis oil, was registered for the treatment of multiple sclerosis. Another cannabis based drug, Epydiolex, was registered in October 2020 as a treatment for certain kinds of epilepsy. Since 2017, pharmaceutical cannabis from the Netherlands and Canada has also been available for patients under license.
The number of medical cannabis patients in Sweden is increasing steadily, from about 500 patients in 2018 to about 2000 patients in 2020. The prognosis for 2021 is that over 4000 patients will have prescriptions for medical cannabis.
Questions about the pain clinic Aureum Healthcare in Stockholm, or its owner the cannabis investment company Aureum Life can be answered by the press spokesperson for the companies, Christian Engström.
More information about the cannabis oils, the process that made them available to pain patients in Sweden, and why this matters can be found in an independent article that will be published at Cannabis i Fokus  shortly. Cannabis i Fokus is Swedens fastest growing news site focused on news regarding cannabis.
Cannabis in focus is a Swedish news magazine about cannabis and was launched on April 20, 2021. The magazine is politically independent and does not take a stand for a party or on individual issues. The editorial staff works instead to make the magazine a platform that gathers all the news, knowledge and conversations about cannabis.
All articles published in the journal must be based on facts, empirical research and recognized methods. We lean on journalistic principles and are careful with our sources.